This technology focuses on improving mitochondrial health in autosomal dominant polycystic kidney disease (ADPKD) to slow or reverse cyst growth, utilizing agents that modulate metabolism in animal models. Seeking partnerships for agent identification and procurement.
This research proposes a novel approach to treating autosomal dominant polycystic kidney disease (ADPKD) by enhancing mitochondrial health. By utilizing agents that improve mitochondrial function, the goal is to slow or even reverse cyst growth in kidney models. ADPKD is a significant genetic disorder affecting 1 in 500 individuals, leading to kidney failure in a majority of cases by age 60. The proposed solution leverages animal models and translational studies, making it a promising candidate for future therapeutic applications.
Key features:
The technology is at TRL 6, indicating that it has been validated in relevant animal models and is ready for further translational studies in human subjects. The research team is seeking partnerships to assist in the identification and procurement of metabolic health-improving agents.
USC is a large, comprehensive private research university in Los Angeles, anchored by two urban campuses and an academic health system. Industry engages through applied research institutes such as the Information Sciences Institute, co-located engineering and clinical facilities, and flexible sponsored research contracting. Proximity to the region’s aerospace, media, and biotech corridors provides access to testbeds, talent, and pilot-scale partners across the greater L.A. innovation economy. Research is supported by competitive federal funding from NIH, NSF, and other major agencies alongside significant industry-sponsored awards. A dedicated technology transfer office supports IP strategy, licensing, corporate partnerships, and venture formation.